Skip to main content

Table 1 Neoplastic and non-neoplastic lesions observed in hepatic tissue of female Sprague-Dawley rats following 104 weeks of chronic p.o. exposure

From: Toxicogenomic analysis of exposure to TCDD, PCB126 and PCB153: identification of genomic biomarkers of exposure to AhR ligands

  100 ng/kg/day TCDD 30 ng/kg/day PCB126 300 ng/kg/day PCB126 1000 ng/kg/day PCB126 1000 μg/kg/day PCB153
Number of Rats Examined 53 55 53 53 53
Hepatocyte Hypertrophy 52**a 23** 42**a 49**a 39**a
Multinucleated Hepatocytes 51**b 2 19** 49**b NA
Fatty Change, Diffuse 48**b 7 30** 47**b 21**
Bile Duct Hyperplasia 53**b 7 14** 45**b 10
Bile Duct Cyst 21** 6 3 12* NA
Oval Cell, Hyperplasia 53** 1 10** 40** NA
Necrosis 17** 2 11 17** NA
Pigmentation 53**b 11** 48**b 48**b 5
Eosiniphilic Focus 44** 10 17 17 NA
Inflammation 49** 40 51** 51** NA
Nodular Hyperplasia 36** NA 3 39** 1
Portal Fibrosis 27** NA 2 10** NA
Cholangiofibrosis 31** 1 3 22** 1
Toxic Hepatopathy 53**b 6* 39** 49**b NA
Hepatocholangioma 17** NA NA 3 2
Hepatocellular Adenoma 13** 2 2 7* NA
Cholangiocarcinoma 25** NA 5* 22** NA
  1. Shown are the number of animals in each treatment group which exhibit the indicated liver pathology following exposure to TCDD (100 ng/kg/day), PCB126 (30, 300 or 1000 ng/kg/day) or PCB153 (1000 μg/kg/day). Data acquired from the National Toxicology Program [4, 5, 8]. a Response also significantly increased (p ≤ 0.01) following 13 and 52 weeks of exposure; b Response also significantly increased (p ≤ 0.01) following 52 weeks of exposure; * Statistically significant when compared to control with p-value ≤ 0.05; ** Statistically significant when compared to control with p-value ≤ 0.01; NA - not available.